Exparel, a product of Pacira Pharmaceuticals (NASDAQ:PCRX), is one of the leading non-opioid analgesics in pain management. Pacira is a rising specialty pharmaceutical company focused on hospital-based products for pain management. It is well known for its DepoFoam Technology, an injectable drug delivery technology that allows both immediate and sustained release of therapies. Its established product DepoCyt is used for treating cancer-related lymphomatous meningitis.
I believe that the company has tremendous growth potential due to its anesthetic product Exparel, which is currently approved only for use via surgical wound infiltration. The positive results from the first part of its Phase II/III study testing Exparel as a single-dose injection through femoral nerve block in patients undergoing total knee...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|